Myeloproliferative Neoplasms

Top Story

Data on antithrombotic therapy for essential thrombocythemia ‘imprecise, inconsistent’

Data on antithrombotic therapy for essential thrombocythemia ‘imprecise, inconsistent’
June 26, 2017

Whether the benefits of antithrombotic therapy outweigh the risks in patients with essential thrombocythemia is unclear based on insufficient evidence, according to a systematic review published in Annals of Internal Medicine.

“The available evidence is imprecise, inconsistent and at high risk [for] bias,” Deborah M. Siegal, MD, MSc, assistant professor in the department of medicine at McMaster University, and colleagues wrote. “Adequately powered randomized trials are needed to clarify the net clinical benefit of antithrombotic therapy in essential thrombocythemia and the subgroups that will derive the most benefit.”

Biden Cancer Initiative seeks to inject urgency into cancer research, foster hope for patients

June 26, 2017
Former Vice President Joe Biden and his wife, Jill Biden, PhD, launched the Biden Cancer Initiative today. The venture is intended to further progress in cancer…
In the Journals

Clonal hematopoiesis of indeterminate potential increases CHD risk

June 26, 2017
Patients who have clonal hematopoiesis of indeterminate potential in peripheral blood cells had an elevated risk for CHD, according to a study published in The New

Seattle Genetics halts trial of vadastuximab talirine for acute myeloid leukemia

June 19, 2017
Seattle Genetics discontinued a randomized phase 3 trial designed to evaluate vadastuximab talirine for frontline treatment of elderly patients with acute myeloid…
CME

Breakthroughs in the Treatment of Bladder Cancer

This activity is supported by an educational grant from Bristol-Myers Squibb.

Assessment of immune checkpoint blockade inhibitors in the treatment of bladder cancer have demonstrated significant…
More »
Video
Meeting News Coverage

VIDEO: New approaches demonstrate potential to exploit immune system to treat cancer

April 30, 2016
More »
Featured

CME

Bridging the Gap from Knowledge to Practice in CRPC

This activity is supported by educational funding provided by AbbVie Inc.; Astellas Scientific and Medical Affairs, Inc. and Medivation; and Sanofi US.

The selection of therapy for patients with castration-resistant prostate cancer (CRPC) remains challenging. Review…
More »
In the Journals Plus

Data on antithrombotic therapy for essential thrombocythemia ‘imprecise, inconsistent’

June 26, 2017
Whether the benefits of antithrombotic therapy outweigh the risks in

Biden Cancer Initiative seeks to inject urgency into cancer research, foster hope for patients

June 26, 2017
Former Vice President Joe Biden and his wife, Jill Biden, PhD, launched the Biden Cancer Initiative today. The venture is intended to further…

In the Journals

Clonal hematopoiesis of indeterminate potential increases CHD risk

June 26, 2017
Patients who have clonal hematopoiesis of indeterminate potential in peripheral blood cells had an elevated risk for CHD, according to a study…

Seattle Genetics halts trial of vadastuximab talirine for acute myeloid leukemia

June 19, 2017
Seattle Genetics discontinued a randomized phase 3 trial designed to evaluate vadastuximab talirine for frontline treatment of elderly patients with…

Geneticist to lead Vanderbilt cancer center’s health disparities program

June 19, 2017
Tuya Pal, MD, has been appointed associate director of cancer health disparities at Vanderbilt-Ingram Cancer Center. Pal, a clinical geneticist…

10 highlights from the ASCO Annual Meeting

June 16, 2017
This year’s ASCO Annual Meeting, held June 2-6 in Chicago, featured the theme “Making a Difference in Cancer Care With You.” …

UT Health cancer center names director

June 16, 2017
Ruben A. Mesa, MD, has been named director of UT Health San Antonio Cancer Center. The NCI–designated cancer center is part of UT Health San…

Oral contraceptive use does not increase long-term cancer risk

June 14, 2017
Women who used oral contraceptives did not demonstrate increased long-term cancer risk, according to results of the Royal College of General…

Meeting News

Momelotinib noninferior to ruxolitinib for spleen response in myelofibrosis

June 13, 2017
CHICAGO — Spleen response with momelotinib appeared noninferior to that of ruxolitinib among treatment-naive patients with myelofibrosis…

Meeting NewsVideo

VIDEO: Visiting expert program helps community providers learn about immuno-oncology

June 12, 2017
CHICAGO — Jarushka Naidoo, MBBCh, spoke with HemOnc Today at the ASCO Annual Meeting about the Institute for Clinical Immuno-Oncology. The…

More Headlines »
Advertisement
Advertisement